Health System Reform Crucial For ATMPs
The difficulties in getting advanced therapies, such as Novartis’ CAR-T therapy Kymriah, to patients have shifted and manufacturing capacity is no longer the biggest issue.
You may also be interested in...
A joint statement from the European Medicines Agency and Heads of Medicines Agencies on biosimilar interchangeability is “concerning,” says Europe’s R&D-based industry federation, EFPIA.
Slovakia has introduced a new system for agreeing managed entry agreements that will make it easier for companies to get their innovative medicines to the market.
New platform for finding solutions to increase access to expensive medicines should ensure sustainability of health care systems and pharmaceutical industry and could include tiered pricing models.